On July 9, 2021, the Biden White House has issued an Executive Order on competition which includes opposition to the Trump effort to narrow Bayh-Dole march-in rights over pricing concerns. This is the first time since 1995 there has been… Continue Reading
On June 28, 2021, KEI sent a memorandum to Gayle E Smith (State), Eric Lander (OSTP), Loyce Pace (HHS) and Samantha Power (USAID), asking the U.S. government to clarify that its sanctions against Cuba do not extend to activities and… Continue Reading
The comments focusing on geographic scope, pricing, manufacturing know-how and transparency. June 2, 2021 Daniel Lee, J.D., Technology Transfer and Patent Specialist, National Institute of Allergy and Infectious Diseases Technology Transfer and Intellectual Property Office Via daniel.lee5@nih.gov Re: Prospective Grant… Continue Reading
HouseOversight-UnsustainableDrugPrices-PartIII-2021 May 19, 2021 Rep. Carolyn B. Maloney Chairwoman of the Committee on Oversight and Reform U.S. House of Representatives Rep. James Comer Ranking Member of the Committee on Oversight and Reform U.S. House of Representatives Re: Request for statement… Continue Reading
KEI comment on the May 5, 2021 USTR statement to support negotiations on a waiver of TRIPS rules for COVID 19 vaccines. Attributed to James Love, KEI Director +1.202.361.3040, james.love@keionline.org KEI applauds the decision by President Biden and USTR Katherine… Continue Reading
KEI will host an online discussion of the new end of Trump term proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes, on January 27, 2021, from 2pm to 4pm. To register for the event, send an email to bayh-dole-proposals@keionline.org… Continue Reading
On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading
On Friday, October 9, 2020, KEI filed a lawsuit in Maryland to obtain documents from five Freedom of Information Act (FOIA) requests filed by KEI related to COVID-19. The cases involve the following issues. The complaint is attached below. FOIA… Continue Reading
(More on KEI’s work on coronavirus here: https://www.keionline.org/coronavirus, and on Moderna, here: https://www.keionline.org/moderna) Oct 8, 2020 Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine… Continue Reading
On Friday, September 18, 2020, KEI received a letter from the Defense Advanced Research Projects Agency (DARPA) confirming that the agency was investigating Moderna for failure to report government funding in patent applications. The Financial Times and other outlets had… Continue Reading